Home/Filings/4/0000899243-21-022894
4//SEC Filing

Booth Andrew 4

Accession 0000899243-21-022894

CIK 0001703057other

Filed

Jun 8, 8:00 PM ET

Accepted

Jun 9, 8:30 PM ET

Size

12.0 KB

Accession

0000899243-21-022894

Insider Transaction Report

Form 4
Period: 2021-06-07
Booth Andrew
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Share Option (right to buy)

    2021-06-07600,000300,000 total
    Exercise: $0.19Exp: 2026-06-15Common Shares (600,000 underlying)
  • Exercise/Conversion

    Common Shares

    2021-06-07$0.32/sh+600,000$192,0001,200,000 total
  • Exercise/Conversion

    Common Shares

    2021-06-07$0.19/sh+600,000$114,000600,000 total
  • Exercise/Conversion

    Share Option (right to buy)

    2021-06-07600,0004,950,000 total
    Exercise: $0.32Exp: 2029-08-22Common Shares (600,000 underlying)
Holdings
  • Common Shares

    (indirect: By Spouse)
    116,959
Footnotes (2)
  • [F1]The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.
  • [F2]2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Issuer

AbCellera Biologics Inc.

CIK 0001703057

Entity typeother

Related Parties

1
  • filerCIK 0001834411

Filing Metadata

Form type
4
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 8:30 PM ET
Size
12.0 KB